Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma In Vitro Ladarixin inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 (IC 50 at 0.7 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Ladarixin (10 mg/kg; p.o. once a day) reduces allergic airway inflammation in a model of single OVA exposure. Ladarixin reduces allergic airway inflammation, remodeling, and bronchial hyperreactivity in a model of chronic OVA exposure . Ladarixin (10 mg/kg; p.o. once a day for 8 days) reduces pulmonary inflammation and fibrosis induced by bleomycin in mice . Ladarixin (10 mg/kg; p.o. once a day for 3 days) protects mice from cigarette smoke-induced exacerbation of influenza-A infection . Ladarixin is also effective in decreasing CXCL8-induced polymorphonuclear leukocyte infiltration in several animal models without a significant dose-related reduction in systemic neutrophil counts. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice (cigarette smoke-induced exacerbation of Influenza-A infection model) Dosage: 10 mg/kg Administration: P.o. once a day at days 2, 3 and 4 post-infection Result: Significantly attenuated the exacerbation in lethality and respiratory changes noted in CSFlu group. Form:Solid IC50& Target:CXCR1 CXCR2